Merck’s Hepatitis C Drug Works
Share
Follow Us
The Editors at Hepatitis Central
April 13, 2015
Learn more about grazoprevir/elbasvir, Merck’s Hepatitis C drug that has been fast-tracked for FDA approval.
FDA Grants Breakthrough Designations to Merck’s Hepatitis C Candidate
The FDA has granted 2 breakthrough therapy designations to Merck’s chronic hepatitis C virus (HCV) candidate, grazoprevir/elbasvir.
The once-daily, single-tablet regimen originally received breakthrough therapy status for the treatment of chronic HCV genotype 1 (GT1) infection in October 2013. However, the FDA rescinded it in January 2015.
Continue reading this entire article:
http://www.pharmacytimes.com/product-news/FDA-Grants-Breakthrough-Designations-to-Mercks-Hepatitis-C-Candidate
